These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8357180)

  • 1. Production of interferon gamma and interleukin-2 by peripheral blood lymphocytes of patients with myasthenia gravis and other autoimmune diseases.
    Mokhtarian F; Shirazian D; Grob D
    Ann N Y Acad Sci; 1993 Jun; 681():315-8. PubMed ID: 8357180
    [No Abstract]   [Full Text] [Related]  

  • 2. Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis.
    Ahlberg RE; Pirskanen R; Lefvert AK
    Clin Immunol Immunopathol; 1991 Jul; 60(1):93-105. PubMed ID: 1904332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release of lymphokines following Epstein-Barr virus infection in vitro of blood lymphocytes from patients with autoimmune diseases.
    Lotz M; Tsoukas CD; Hench PK; Carson DA; Vaughan JH
    Trans Assoc Am Physicians; 1986; 99():114-24. PubMed ID: 2440173
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis.
    Jander S; Stoll G
    Neurology; 2002 Jul; 59(2):287-9. PubMed ID: 12136075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells with specificity for idiotypic determinants on human monoclonal autoantibodies in myasthenia gravis.
    Yi Q; Ahlberg R; Lefvert AK
    Res Immunol; 1992 Feb; 143(2):149-56. PubMed ID: 1574640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro effects of D-penicillamine upon anti-AChR production by thymic and peripheral blood lymphocytes from patients with myasthenia gravis.
    Scadding GK; Calder L; Newsom-Davis J
    Muscle Nerve; 1983; 6(9):656-60. PubMed ID: 6606776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma is required to induce experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; Orn A; van der Meide PH; Link H
    Ann N Y Acad Sci; 1998 May; 841():576-9. PubMed ID: 9668299
    [No Abstract]   [Full Text] [Related]  

  • 8. Responsiveness of myasthenia gravis lymphocytes to recombinant interleukin-2.
    Cohen-Kaminsky S; Berrih-Aknin S; Safar D
    Ann N Y Acad Sci; 1988; 540():506-7. PubMed ID: 3264679
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
    McIntosh KR; Linsley PS; Drachman DB
    Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of interleukin (IL)-21 and CD4
    Alahgholi-Hajibehzad M; Durmuş H; Aysal F; Gülşen-Parman Y; Oflazer P; Deymeer F; Saruhan-Direskeneli G
    Clin Exp Immunol; 2017 Nov; 190(2):201-207. PubMed ID: 28671717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte activation in experimental autoimmune myasthenia gravis.
    De Baets MH; Einarson B; Lindstrom JM; Weigle WO
    J Immunol; 1982 May; 128(5):2228-35. PubMed ID: 6977589
    [No Abstract]   [Full Text] [Related]  

  • 12. Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.
    Merrill JE; Graves MC; Mulder DG
    West J Med; 1992 Jun; 156(6):639-46. PubMed ID: 1319627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of T cell subpopulations and recombinant interleukin (IL)-2 on peripheral B cell function in patients with myasthenia gravis.
    Zhang J; Zhou WB; Wang HL; Guo SS
    Hum Antibodies; 1997; 8(2):90-4. PubMed ID: 9289393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte function in myasthenia gravis.
    Kawanami S; Kanaide A; Itoyama Y; Kuroiwa Y
    J Neurol Neurosurg Psychiatry; 1979 Aug; 42(8):734-40. PubMed ID: 490180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoreactive T and B cells in nervous system diseases.
    Sun JB
    Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental myasthenia gravis.
    Goldstein G; Hofmann WW
    Res Publ Assoc Res Nerv Ment Dis; 1971; 49():241-59. PubMed ID: 4329690
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of B-cells in experimental myasthenia gravis in mice.
    Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
    Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon system and natural killer cell activity in myasthenia gravis.
    Kott E; Hahn T; Huberman M; Levin S; Schattner A
    Q J Med; 1990 Sep; 76(281):951-60. PubMed ID: 1700449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of interleukin-2 on interferon production by human lymphocytes and the importance of this test in autoimmune diseases].
    Protasova SF; Shchekanova SM; Nazarov PG; Vasil'evykh LA; Rudenko DI; Lobzin VS; Barklai-de-Tolli MN
    Vestn Ross Akad Med Nauk; 1996; (1):54-6. PubMed ID: 8907428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The significance of lymphocytes E rosette-formation rate in cerebrospinal fluid and peripheral blood (author's transl)].
    Zhang YH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Nov; 14(4):238-41. PubMed ID: 7343236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.